|
Hyperimmune globulin therapy is concentrated immunoglobulins used to treat patients whose immune
systems have been compromised. Constant monitoring in steps of the manufacturing and delivery process
make these biological products safe, easy, and convenient to use. A doctor or healthcare provider
prescribes hyperimmune globulin therapies.
Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition,
approved indications (uses), product labels, and packaging for a prescription drug may differ between
countries. Please refer to the prescribing information provided for your country of residence.
Hypermunes™ Hyperimmune Globulin Therapy reaches patients around the world, including in:
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|